Extended Follow-Up and Impact of High-Risk Prognostic Factors From the Phase 3 RESONATE Study in Patients With Previously Treated CLL/SLL

Leukemia - United Kingdom
doi 10.1038/leu.2017.175
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Patterns of Duvelisib-Induced Lymphocytosis in Patients With R/R CLL or SLL Including Those With High-Risk Factors Treated in the Duo Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib Versus Temsirolimus: 3-Year Follow-Up of Patients With Previously Treated Mantle Cell Lymphoma From the Phase 3, International, Randomized, Open-Label RAY Study

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2018English

Long-Term Follow-Up of the RESONATE™ Phase 3 Trial of Ibrutinib Versus Ofatumumab

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

Predictors of Sudden Cardiac Death in Never Previously Treated Patients With Essential Hypertension: Long-Term Follow-Up

Journal of Human Hypertension
Internal Medicine
2001English

Extended Follow-Up of Treated and Untreated Retinopathy in Incontinentia Pigmenti

JAMA Ophthalmology
Ophthalmology
2015English

Risk Factors for Fall in Elderly Patients: Follow-Up Study After Hospital Discharge

Open Journal of Internal Medicine
2018English

Prognostic Factors for Patients Treated With Abiraterone

Future Science OA
MedicineBiotechnology
2019English

Risk for High Depressive Symptoms in Diagnosed and Previously Undetected Diabetes: 5-Year Follow-Up Results of the Heinz Nixdorf Recall Study

PLoS ONE
Multidisciplinary
2013English

Atezolizumab in Japanese Patients With Previously Treated, Advanced Non–small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy